Is there evidence of clinical benefit for the use of nasal Synapsin (Ginsenosides) in patients?

From the Guidelines

There is currently no substantial evidence supporting clinical benefits for nasal Synapsin containing RG3 ginsenosides. The provided evidence 1 focuses on the diagnosis and management of rhinitis, discussing various treatment options such as oral antihistamines, intranasal corticosteroids, and leukotriene receptor antagonists, but does not mention nasal Synapsin or RG3 ginsenosides. Key points to consider in the management of rhinitis include:

• The use of intranasal corticosteroids as the most effective medication class for controlling symptoms of allergic rhinitis 1
• The role of oral antihistamines and leukotriene receptor antagonists in reducing symptoms of allergic rhinitis 1
• The importance of considering the potential side effects of treatments, such as sedation and anticholinergic effects with first-generation antihistamines 1 Given the lack of evidence supporting the use of nasal Synapsin, patients should consult healthcare providers about evidence-based therapies rather than using supplements with unproven benefits. Until properly designed clinical trials demonstrate efficacy, nasal Synapsin with RG3 ginsenosides should not be recommended as a treatment for any medical condition, prioritizing morbidity, mortality, and quality of life as the outcome.

From the FDA Drug Label

For the temporary relief of: Nasal Congestion Rhinitis and Sinusitis Cold and Flu Nasal Symptoms The FDA drug label does not answer the question.

From the Research

Clinical Benefit of Nasal Synapsin (RG3 ginsenosides)

• There is limited direct evidence on the clinical benefit of nasal Synapsin (RG3 ginsenosides) in the provided studies.
• However, a study on ginsenosides, which are components of Panax ginseng, found that Rg3(S) and Rg5/Rk1 had memory-enhancing and neuroprotective effects in mice 2.
• The study found that these ginsenosides ameliorated memory impairment induced by ethanol and scopolamine, and inhibited excitotoxicity induced by glutamate or N-methyl-D-aspartate (NMDA) in primary cultured rat cortical cells 2.
• Another study discussed the role of synapsin III in neuronal plasticity and disease, but did not provide direct evidence on the clinical benefit of nasal Synapsin (RG3 ginsenosides) 3.
• The other studies provided do not have relevant information on the clinical benefit of nasal Synapsin (RG3 ginsenosides) 4, 5, 6.